Article Details

RedHill Biopharma highlights strong end to first-quarter and almost 100% enrollment in opaganib's ...

Retrieved on: 2021-06-01 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

RedHill Biopharma highlights strong end to first-quarter and almost 100% enrollment in opaganib's .... View article details on hiswai:

Excerpt

RedHill Biopharma Ltd (NASDAQ:RDHL) has reported its financial results and operational highlights for the first quarter ended March 31, 2021, with ...

Article found on: www.proactiveinvestors.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up